Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial

Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement

(2019) Brian L. Graham et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

(2019) Harry G M Heijerman et al.   LANCET

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microbiology of Cystic Fibrosis Airway Disease

(2019) Ana C. Blanchard et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections

(2016) Estrella Rojo-Molinero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

(2016) Patrick A. Flume et al.   Journal of Cystic Fibrosis

RORγt+ cells selectively express redundant cation channels linked to the Golgi apparatus

(2016) Lucile Drujont et al.   Scientific Reports

Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets

(2015) Michelle L Robinette et al.   NATURE IMMUNOLOGY

Versican and the control of inflammation

(2014) Thomas N. Wight et al.   MATRIX BIOLOGY

Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis

(2013) J A Nick et al.   THORAX

Sputum Biomarkers of Inflammation and Lung Function Decline in Children with Cystic Fibrosis

(2012) Scott D. Sagel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

(2012) Baroukh M. Assael et al.   Journal of Cystic Fibrosis

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)

(2011) C. M. Oermann et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

(2010) Michael W. Konstan et al.   Journal of Cystic Fibrosis

Tmem176B and Tmem176A are associated with the immature state of dendritic cells

(2010) Thomas Condamine et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Phylogenetic Analysis of the MS4A and TMEM176 Gene Families

(2010) Jonathan Zuccolo et al.   PLoS One

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

(2009) George Z. Retsch-Bogart et al.   CHEST

Circulating RNA Transcripts Identify Therapeutic Response in Cystic Fibrosis Lung Disease

(2008) Milene T. Saavedra et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Inhaled Aztreonam Lysine for Chronic AirwayPseudomonas aeruginosain Cystic Fibrosis

(2008) Karen S. McCoy et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE